icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
Triple Therapy With Daclatasvir (DCV; BMS-790052), Peginterferon Alfa-2a and Ribavirin in HCV-Infected Prior Null and Partial Responders: 12-Week Results of Phase 2b COMMAND-2 Trial
 
 
  Reported by Jules Levin
EASL 2012
Apr 18-22 Barcelona Spain
 
Ratziu V,1 Gadano A,2 Pol S,3 Hezode C,4 Ramji A,5 Cheng W,6 Sulkowski M,7 Everson GT,8 Diva U,9 McPhee F,9 Wind-Rotolo M,10 Hughes EA,10 Yin PD,9 Schnittman S,9 for the COMMAND-2 Investigators 1Hôpital Pitie Salpêtriere, Paris, France; 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 3Hôpital Cochin, Paris, France; 4 CHU Henri Mondor, Creteil, France; 5Gastrointestinal Research Institute, Vancouver, Canada; 6Royal Perth Hospital, Perth, Australia; 7Johns Hopkins University, Lutherville, MD, USA; 8University of Colorado-Denver, Aurora, CO, USA; 9Bristol-Myers Squibb, Wallingford, CT, USA; 10Bristol-Myers Squibb, Princeton, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif